Trial Profile
A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 22 Feb 2022
Price :
$35
*
At a glance
- Drugs Lyophilised Oxalobacter formigenes (Primary)
- Indications Hyperoxaluria
- Focus Therapeutic Use
- Sponsors OxThera
- 30 Sep 2014 New trial record